Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma

J Thorac Oncol. 2018 Jan;13(1):e9-e12. doi: 10.1016/j.jtho.2017.08.025.

Authors

Biagio Ricciuti¹, Giulio Metro², Marta Brambilla², Vienna Ludovini², Sara Baglivo², Annamaria Siggillino², Enrico Prosperi³, Rita Chiari²

Affiliations

¹ Medical Oncology, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy. Electronic address: biagio.ricciuti@gmail.com.
² Medical Oncology, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.
³ Department of Experimental Medicine, Division of Pathology and Histology, University of Perugia Medical School, Perugia, Italy.

PMID: 29258673
DOI: 10.1016/j.jtho.2017.08.025

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Afatinib / pharmacology
Afatinib / therapeutic use*
Aged
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / pathology
Disease Progression
Drug Resistance, Neoplasm / drug effects*
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / pathology

Substances

Antineoplastic Agents
Afatinib